United States was Revvity’s largest region in fiscal 2025, bringing in $1.13B of $2.86B (39%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.68B | $1.55B | $1.12B | $1.10B | $1.13B | ||||||||||||
| Other International | $1.34B | $1.15B | $859.90M | $931.71M | $1.00B | ||||||||||||
| China | $449.59M | $476.37M | $454.43M | $450.01M | $425.06M | ||||||||||||
| United Kingdom | $357.91M | $136.02M | $125.42M | $112.88M | $126.85M | ||||||||||||
| Germany | — | — | $193.17M | $162.58M | $177.66M | ||||||||||||
| Japan | — | — | — | — | — | ||||||||||||
| France | — | — | — | — | — | ||||||||||||
| Italy | — | — | — | — | — | ||||||||||||
| India | — | — | — | — | — | ||||||||||||
| Korea, Republic Of | — | — | — | — | — | ||||||||||||
| Total | $3.83B | $3.31B | $2.75B | $2.76B | $2.86B |
Revvity brought in $2.86B from its five regions in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. United States was the largest at $1.13B (39.4%), ahead of Other International at $1.00B (35.0%) and China at $425.06M (14.9%). The other two regions brought in $304.51M combined.
Compared with fiscal 2024, United Kingdom grew fastest, up 12.4% to $126.85M, while China fell the most, down 5.5% to $425.06M.
Life Sciences Solutions was Revvity’s largest revenue line in fiscal 2025, bringing in $1.19B of $2.86B (42%).
| Major goods/service lines | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Life Sciences Solutions | — | — | $1.28B | $1.20B | $1.19B |
| Immunodiagnostics | $1.80B | $1.11B | $787.39M | $828.63M | $869.91M |
| Life Sciences Reagents | $399.52M | $691.34M | — | — | — |
| Reproductive Health | $514.86M | $516.57M | $504.99M | $527.80M | $555.04M |
| Applied Genomics | $619.36M | $393.60M | — | — | — |
| Life Sciences Instruments | $329.58M | $405.55M | — | — | — |
| Software | — | — | $178.29M | $200.80M | $236.38M |
| Life Sciences Software | $166.77M | $196.01M | — | — | — |
| Total | $3.83B | $3.31B | $2.75B | $2.76B | $2.86B |
Revvity brought in $2.86B from its four revenue lines in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. Life Sciences Solutions was the largest at $1.19B (41.8%), ahead of Immunodiagnostics at $869.91M (30.5%) and Reproductive Health at $555.04M (19.4%). The remaining revenue line, Software, brought in $236.38M.
Compared with fiscal 2024, Software grew fastest, up 17.7% to $236.38M, while Life Sciences Solutions fell the most, down 0.3% to $1.19B.
Revvity began breaking out Life Sciences Solutions in fiscal 2023 and Software in fiscal 2023. Revvity stopped reporting Life Sciences Reagents ($691.34M in fiscal 2023), Life Sciences Instruments ($405.55M in fiscal 2023), Applied Genomics ($393.60M in fiscal 2023) and one other as separate revenue lines.
Life Sciences was Revvity’s largest segment in fiscal 2025, bringing in $1.43B of $2.86B (50%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Discovery & Analytical Solutions | — | — | — | — | — | ||||||||||||
| Diagnostics | $2.93B | $2.02B | $1.29B | $1.36B | $1.42B | ||||||||||||
| Life Sciences | $895.87M | $1.29B | $1.46B | $1.40B | $1.43B | ||||||||||||
| Human Health | — | — | — | — | — | ||||||||||||
| Environmental Health | — | — | — | — | — | ||||||||||||
| Total | $3.83B | $3.31B | $2.75B | $2.76B | $2.86B |
Revvity brought in $2.86B from its two segments in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. Life Sciences was the largest at $1.43B (50.1%), ahead of Diagnostics at $1.42B (49.9%).
Compared with fiscal 2024, Diagnostics grew 5.1% to $1.42B and Life Sciences grew 2.3% to $1.43B. From fiscal 2022 to 2025, combined revenue from these segments fell from $3.83B to $2.86B, a compound annual decline of 9.3%. Life Sciences' share of the total rose from 23.4% to 50.1%.
Revvity (RVTY) reports its revenue by geography, by major goods/service lines and by segment. In fiscal 2025, United States was its largest region, bringing in $1.13B (39.4% of the total), followed by Other International at $1.00B (35.0%).
United States was Revvity's largest region in fiscal 2025, bringing in $1.13B, or 39.4% of the $2.86B total across its five regions.
Life Sciences Solutions was Revvity's largest revenue line in fiscal 2025, bringing in $1.19B, or 41.8% of the $2.86B total across its four revenue lines.
Life Sciences was Revvity's largest segment in fiscal 2025, bringing in $1.43B, or 50.1% of the $2.86B total across its two segments.
Among Revvity's regions that make up at least 2% of revenue, United Kingdom grew fastest in fiscal 2025, up 12.4% from $112.88M to $126.85M.
Every figure comes from Revvity's annual financial filings, as reported. Each line keeps the name Revvity gives it, and years follow its fiscal calendar.
Revvity's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.